In July 2013, YUKEMI PHARM entered into a co-promotion agreement with Daewoong Pharmaceutical for an integrated kit formulation of antibiotics and infusion solutions, known as the Integrated Injection Kit.

Under this strategic partnership for sales and marketing, YUKEMI PHARM supplied the kit injection product to Daewoong for three years. However, during the term of the co-promotion agreement, Daewoong Pharmaceutical independently registered and obtained a patent for the Integrated Injection Kit in March 2016.

After discovering this fact post hoc, YUKEMI PHARM terminated the co-promotion agreement in October 2016 and subsequently filed a patent invalidation trial against Daewoong’s Integrated Injection Kit patent.

Following a lengthy review, the Intellectual Property Tribunal ruled in favor of YUKEMI PHARM on November 26, 2019, and on March 2, 2020, the decision was officially finalized.

Through this victory in the patent dispute with Daewoong Pharmaceutical, YUKEMI PHARM has established a precedent against unjust patent imitation by large corporations.

The Integrated Injection Kit is a sterilely assembled and manufactured injectable product in which drugs such as antibiotics and anticancer agents are combined with diluents (such as normal saline or glucose injection) in a single, integrated form.

As the only kit injection product in the antibiotic injection market, it is recognized for significantly reducing syringe contamination and hospital-acquired infections, which frequently occur in hospital settings. It provides both convenience and safety for antibiotic injections while effectively preventing nosocomial infections.

In summary, this trial resulted in the invalidation of all claims in Daewoong Pharmaceutical’s Patent No. 1631551.